Search
Now showing items 1-2 of 2
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
(Amer Soc Hematology, Washington, 2006)
Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP ...
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
(Amer Soc Hematology, Washington, 2020)